Format

Send to

Choose Destination
Mediators Inflamm. 2014;2014:717598. doi: 10.1155/2014/717598. Epub 2014 May 28.

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.

Author information

1
Department of Ophthalmology, University Hospital of León, 24071 León, Spain ; Uveitis Unit, University Hospital of León, 24071 León, Spain ; Institute of Biomedicine (INBIOMED), University of León, León, Spain.
2
Department of Rheumatology, University Hospital "Marques de Valdecilla", IFIMAV, 39008 Santander, Spain.
3
Department of Ophthalmology, University Hospital "Clínic", 08036 Barcelona, Spain.
4
Department of Rheumatology, University Hospital of León, 24071 León, Spain.
5
Uveitis Unit, University Hospital of León, 24071 León, Spain ; Department of Immunology, University Hospital of León, 24071 León, Spain.
6
Uveitis Unit, University Hospital of León, 24071 León, Spain ; Institute of Biomedicine (INBIOMED), University of León, León, Spain ; Department of Immunology, University Hospital of León, 24071 León, Spain.

Abstract

OBJECTIVE:

To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy.

METHODS:

Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients.

RESULTS:

Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P = 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ, P = 0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed.

CONCLUSIONS:

GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.

PMID:
24976689
PMCID:
PMC4058145
DOI:
10.1155/2014/717598
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center